Ranbaxy got approval to market Amlodipine tablets in Japan

Indian Pharma giant Ranbaxy Lab has received authorization from Ministry of Health and Labour Welfare of Japan for marketing the generic version of Amlodipine tablets 2.5mg & 5mg. Amlodipine tablet is the first independent product approval received by Ranbaxy in Japan. It has the unique distinction of being the first product developed by any foreign generic pharmaceutical company outside Japan and subsequently being granted approval by MHLW (Japan). Amlodipine tablets has a market size of around US $2 billion (Jan-Dec' 2007 - IMS - Japan). The product is currently the largest molecule which has gone off patent in Japan and represents the biggest generic opportunity so far in the Japanese generic market. The Government of Japan is encouraging generic substitution which is reflected in the growing genericization of medicines from 17 per cent by volume in 2007 to 30 per cent by volume in 2012.